United States: Capitol Hill Healthcare Update - November 6, 2017

December Most Likely Timetable for CHIP Even After House Approval

The House last week voted to renew the Children's Health Insurance Program (CHIP) through 2022, but disagreements over how to pay for the program are likely to delay consideration in the Senate beyond this month.

On a mostly party line 242-174 vote, the House adopted the five-year extension along with a renewal of funding for community health centers. But the pay-fors House Republicans had identified – including tapping money from the Affordable Care Act's (ACA's) prevention fund and means-testing Medicare premiums for wealthy beneficiaries – were non-starters for most Democrats.

The Senate Finance Committee has its own version of CHIP renewal legislation that largely mirrors the House's bill, except the Senate has not identified any offsets.

Procedurally and politically, it would be challenging for Senate Republican leaders to schedule a vote on their own CHIP bill, which needs 60 votes to pass. Despite the outcry from advocacy groups and providers, including children's hospitals, it is not likely that the Senate will consider CHIP legislation this month.

Instead, federal funding for CHIP, which expired September 30, is likely to wait until December, when it could be included in catch-all budget legislation.

Bipartisan Majority Votes to Repeal ACA's Independent Payment Advisory Board (IPAB)

The House last week voted overwhelmingly to repeal a controversial Medicare cost-cutting panel.

The House voted 307-111 to repeal the Independent Payment Advisory Board (IPAB), which was created by the ACA. Joining all Republicans, 76 Democrats voted to kill the board.

The IPAB was never officially constituted because Medicare spending has been below the threshold that would automatically create the panel. But the IPAB has generated widespread opposition, not only from lawmakers but also from an array of healthcare providers because of its sweeping powers to make Medicare spending and reimbursement changes.

A Senate version of the bill also enjoys some Democratic support, including from its author, Sen. Ron Wyden (D-Ore.), the top Democrat on the Senate Finance Committee.

House GOP Tax Bill Would Repeal Orphan Drug Tax Credit

House Republicans' sweeping tax overhaul would repeal a tax credit meant to incentivize pharmaceutical manufacturers to invest in rare disease research.

The tax legislation, which the Ways and Means Committee will begin voting on today, would end the Orphan Drug Tax Credit, which allows pharma companies to offset 50 percent of the costs of clinical trials for diseases that affect fewer than 200,000 people. The tax credit reduces revenue to the government by $54 billion over 10 years, according to Congress' Joint Committee on Taxation.

Smaller patient populations dramatically increase the costs for clinical trials, and before the tax credit was created in 1983, the Food and Drug Administration (FDA) approved fewer than 40 orphan drugs. Since then, more than 600 orphan drugs have won FDA approval.

But amid the politics of drug prices, there are questions about whether the tax credit should be reformed. The Senate's version of the overall tax bill is expected to be released later this week by Finance Committee Chairman Orrin Hatch (R-Utah), who was a principal author of the Orphan Drug Tax Credit. This spring, Hatch asked for a Government Accountability Office analysis of whether manufacturers are in effect gaming the system by using multiple designations to subsidize research costs beyond those targeted for rare disease populations.

Brady Weighs Individual Mandate Repeal in Tax Bill

President Trump and some Senate Republicans are advocating that repeal of the ACA's individual mandate be included in the House GOP's tax overhaul.

The Congressional Budget Office estimated that ending the requirement that most Americans purchase health insurance would save $416 billion over 10 years – money congressional Republicans can use to finance additional tax relief.

But the Senate twice this year failed to demonstrate it had 50 votes to partially repeal and replace the ACA. Injecting healthcare into an issue as thorny and politically delicate as taxes would likely complicate passage, especially in the Senate, where Republicans hold a two-seat majority.

House Ways and Means Committee Chairman Kevin Brady (R-Texas) said last week that Republican leaders were weighing the idea of adding a repeal of the individual mandate. But he also acknowledged the complicated politics of including the healthcare provision.

Brady's bill does not include the repeal of any ACA-created provider tax.

Bipartisan Senate Bill Seeks to Reduce 'Drug Waste'

Senate Judiciary Committee Chairman Check Grassley (R-Iowa) introduced legislation last week that seeks to reduce what he called single-use "drug waste."

Grassley said his legislation is aimed at reducing over-sized doses that cause excess spending. The senator pointed to a media report last month that found some pharmaceutical manufacturers produced eye drops in over-sized doses, in some cases more than twice what the eye can hold. A separate New York Times report last year found Medicare and private payers were reimbursed for cancer drugs distributed in vials that held too much medicine for most patients.

Grassley's bill would require the FDA and the Centers for Medicare and Medicaid Services (CMS) to develop a joint action plan to reduce drug waste and better manage drug vial sizes and other drug delivery systems like eye-drops. Sens. Dick Durbin (D-Ill.) and Jeanne Shaheen (D-N.H.) are co-sponsors of the legislation.

Durbin said the legislation would crack down on drug companies that "insist on selling their products in excessively large, one-size-fits-all vials that contain more medicine than the average patient needs [and is] a colossal and completely preventable waste of taxpayer dollars."

Bill Seeks to Slow 'Revolving Door' Between Pharma, Government

Legislation introduced in the Senate last week would prohibit former FDA and Drug Enforcement Administration officials from assisting pharmaceutical manufacturers in federal lobbying efforts.

Introduced by seven Democratic senators – led by Sen. Tammy Baldwin (D-Wis.) – the bill would establish a two-year "cooling off" period during which former agency officials could not lobby the government or even participate in efforts that would support lobbying.

Baldwin said her bill is designed to prevent potential conflicts of interest.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.